PF-04691502

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NamePF-04691502
Drug Alias NamePF-502PF-4691502PF-1502
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPI3-kinase class I inhibitorsmTOR Complex 2 inhibitorsMammalian target of Rapamycin (mTORC1) inhibitors
TargetsMammalian target of Rapamycin (mTORC1)mTOR Complex 2PI3-kinase class I
Therapy Area/IndicationsEndometrial NeoplasmsBreast NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[11] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsEndometrial NeoplasmsBreast NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A